Flavocure Biotech Inc.: Flavocure Biotech Announces FDA Clearance of IND Application for Caflanone (FBL-03G), for Clinical Trials in Pancreatic Cancer Patients.

IND Clearance for a New Class of Therapeutic Prenylated Phenolic FlavonePhase I Clinical Trial Expected to Launch in 2023 and Will Evaluate the Safety and Preliminary Antitumor Activity of Caflanone in

Related Keywords

,Gewinn Nur ,Ngehj Toyang ,Henry Lowe ,Douglas Liu ,Founder Of Flavocure Biotech Inc ,Drug Administration ,Linkedin ,Maryland Newsfile Corp ,Flavocure Biotech Inc ,Twitter ,New Class ,Therapeutic Prenylated Phenolic ,Clinical Trial Expected ,Will Evaluate ,Preliminary Antitumor Activity ,Investigational New Drug ,Ductal Adenocarcinoma ,Interim Chief Medical Officer ,Flavocure Biotech ,Chief Executive Officer ,Executive Chairman ,Pancreatic Cancer ,Drug Designation ,Flavocure ,Biotech ,Nnounces ,Clearance ,Application ,Aflanone ,Linical ,Trials ,Pancreatic ,Dancer ,Patients ,